1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
  Report
Delayed Nasdaq Copenhagen  -  10:54 2022-08-19 am EDT
37.50 DKK   -2.60%
08/18VIROGATES A/S : Half-Year Report, H1 2022
PU
08/18VIROGATES ANNOUNCES ITS HALF-YEAR REPORT FOR H1 2022 : 62% revenue growth and new EBIT guidance
AQ
08/18ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+

05/25/2022 | 09:43am EDT

ViroGates A/S announces the successful CE-IVD accreditation of its novel point-of-care finger prick analysis product for the detection of suPAR. The suPARnostic® POC+ product now has full CE-IVD accreditation for use in professional healthcare settings to identify inflammation and immune activation by measuring suPAR. The product will be sold under the brand name suPARnostic® POC+.

The suPARnostic® POC+ development is a collaboration between ViroGates, and Austria based GENSPEED Biotech GmbH and is based on the GENSPEED Technology that allows for quick and fully automated processing of finger-prick blood to help the hospital sector to triage patients better and faster. The analysis takes approximately 20 minutes to conduct. The product can potentially incorporate more biomarkers into the same panel in the future.

ViroGates and GENSPEED attempted to incorporate C-reactive protein during the product development phase, but the results were not within the required quality for clinical use. The plan is to run a comprehensive handling study with a clinical partner to ensure that all product features are adequate in the clinical setting before a full commercial rollout. The commercial rollout is expected to start in First Quarter 2023 and will not have a financial impact on 2022 results.


© S&P Capital IQ 2022
All news about VIROGATES A/S
08/18VIROGATES A/S : Half-Year Report, H1 2022
PU
08/18VIROGATES ANNOUNCES ITS HALF-YEAR RE : 62% revenue growth and new EBIT guidance
AQ
08/18ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/15VIROGATES A/S : Higher suPAR is associated with incident venous thromboembolism independen..
PU
07/15ViroGates notification of transactions by persons discharging managerial responsibiliti..
AQ
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
PU
06/20Invitation to ViroGates' investor meeting
AQ
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
AQ
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
PU
More news
Financials
Sales 2021 7,66 M 1,04 M 1,04 M
Net income 2021 -17,7 M -2,41 M -2,41 M
Net cash 2021 14,9 M 2,02 M 2,02 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 129 M 17,6 M 17,6 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 50,4%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-73.26%18
EXACT SCIENCES CORPORATION-50.56%6 809
GUARDANT HEALTH, INC.-49.65%5 148
BGI GENOMICS CO., LTD.-30.11%3 706
IOVANCE BIOTHERAPEUTICS, INC.-35.15%1 954
VERACYTE, INC.-44.61%1 633